Thomas Grinda

481 total citations
25 papers, 76 citations indexed

About

Thomas Grinda is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Thomas Grinda has authored 25 papers receiving a total of 76 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in Thomas Grinda's work include Cancer Treatment and Pharmacology (11 papers), Advanced Breast Cancer Therapies (8 papers) and HER2/EGFR in Cancer Research (8 papers). Thomas Grinda is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Advanced Breast Cancer Therapies (8 papers) and HER2/EGFR in Cancer Research (8 papers). Thomas Grinda collaborates with scholars based in France, United States and Italy. Thomas Grinda's co-authors include Barbara Pistilli, Elie Rassy, Paolo Tarantino, Sara M. Tolaney, Eric P. Winer, Maryam B. Lustberg, Cary P. Gross, Ian E. Krop, Pamela R. Soulos and Nancy U. Lin and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Thomas Grinda

20 papers receiving 76 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Grinda France 5 55 25 17 14 12 25 76
Vichitra Behel India 6 44 0.8× 50 2.0× 12 0.7× 32 2.3× 15 1.3× 7 81
Samuel M. Niman United States 5 56 1.0× 24 1.0× 9 0.5× 40 2.9× 16 1.3× 15 76
Qilong Zhang China 4 41 0.7× 29 1.2× 11 0.6× 14 1.0× 10 0.8× 9 50
Olga Ponomarova Ukraine 4 77 1.4× 21 0.8× 8 0.5× 35 2.5× 24 2.0× 13 104
Jagdish Shetty United States 4 79 1.4× 40 1.6× 13 0.8× 12 0.9× 6 0.5× 7 89
Raquel von Schumann Germany 6 56 1.0× 20 0.8× 13 0.8× 58 4.1× 8 0.7× 12 81
Victoria Attaya United States 4 63 1.1× 10 0.4× 20 1.2× 15 1.1× 15 1.3× 6 69
M. Untch Germany 4 40 0.7× 10 0.4× 14 0.8× 15 1.1× 9 0.8× 14 52
Zachary T. Olah United States 2 40 0.7× 23 0.9× 8 0.5× 7 0.5× 10 0.8× 3 55
Samira Bensfia Spain 3 54 1.0× 15 0.6× 9 0.5× 28 2.0× 12 1.0× 9 67

Countries citing papers authored by Thomas Grinda

Since Specialization
Citations

This map shows the geographic impact of Thomas Grinda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Grinda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Grinda more than expected).

Fields of papers citing papers by Thomas Grinda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Grinda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Grinda. The network helps show where Thomas Grinda may publish in the future.

Co-authorship network of co-authors of Thomas Grinda

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Grinda. A scholar is included among the top collaborators of Thomas Grinda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Grinda. Thomas Grinda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Mosele, M.F., et al.. (2025). 79P Molecular features of metastatic breast cancer (MBC) among young adults (YA). ESMO Open. 10. 104633–104633.
3.
Foldi, Julia, Pamela R. Soulos, Cary P. Gross, et al.. (2025). 314P Outcomes with trastuzumab deruxtecan (T-DXd) for metastatic breast cancer (MBC) according to BRCA and PD-L1 status. ESMO Open. 10. 104886–104886.
4.
Tarantino, Paolo, Julia Foldi, Pamela R. Soulos, et al.. (2025). Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer. JNCI Journal of the National Cancer Institute. 117(11). 2327–2335. 4 indexed citations
5.
Morganti, Simonetta, Melissa E. Hughes, Thomas Grinda, et al.. (2025). Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer. ESMO Open. 10(10). 105828–105828.
6.
Grinda, Thomas, Ayal A. Aizer, Nancy U. Lin, & Sarah Sammons. (2025). Central Nervous System Metastases in Breast Cancer. Current Treatment Options in Oncology. 26(1). 14–35. 1 indexed citations
7.
Valle, Ítalo Faria do, Thomas Grinda, Lorenzo Antonuzzo, & Barbara Pistilli. (2025). Antibody–drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives. npj Breast Cancer. 11(1). 102–102. 3 indexed citations
8.
Grinda, Thomas, Stefania Morganti, Liangge Hsu, et al.. (2025). Real-World outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases. npj Breast Cancer. 11(1). 22–22. 2 indexed citations
9.
Papa, Francesca, Thomas Grinda, Elie Rassy, et al.. (2024). Long road towards effective HER3 targeting in breast cancer. Cancer Treatment Reviews. 129. 102786–102786. 5 indexed citations
10.
Pellat, Anna, Thomas Grinda, Arsela Prelaj, et al.. (2024). Characteristics and impact of real-world evidence studies in oncology: comprehensive mapping review of publications evaluating targeted therapies in solid tumours. SHILAP Revista de lepidopterología. 6. 100091–100091. 1 indexed citations
11.
Benvenuti, C., Thomas Grinda, Elie Rassy, et al.. (2024). Unveiling the Potential of Cyclin-Dependent Kinases 4 and 6 Inhibitors Beyond Progression in Hormone Receptor Positive/Human Epidermal Growth Factor Negative Advanced Breast Cancer – A Clinical Review. Current Treatment Options in Oncology. 25(12). 1517–1537. 3 indexed citations
12.
13.
Grinda, Thomas, Stefania Morganti, Liangge Hsu, et al.. (2024). NVTG-04 REAL-WORLD OUTCOMES WITH SACITUZUMAB GOVITECAN AMONG BREAST CANCER PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) METASTASES. Neuro-Oncology Advances. 6(Supplement_1). i24–i24. 1 indexed citations
14.
15.
Grinda, Thomas, et al.. (2023). Intracranial hypotension in a breast cancer patient treated with epidural blood patches. CNS Oncology. 12(1). CNS94–CNS94.
16.
Dien, Alicia Tran, L. Mignot, Martina Pagliuca, et al.. (2023). 29P Prevalence of high tumor mutational burden (TMB) in patients with metastatic breast cancer (mBC) assessed by liquid biopsy (LB). ESMO Open. 8(1). 101253–101253. 2 indexed citations
17.
Grinda, Thomas, Elie Rassy, & Barbara Pistilli. (2023). Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead. Current Treatment Options in Oncology. 24(5). 442–465. 21 indexed citations
18.
Grinda, Thomas, Sarah Winter, Perry Gerard, et al.. (2023). 1968P Metastatic Ewing sarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study. Annals of Oncology. 34. S1051–S1052. 1 indexed citations
19.
Grinda, Thomas & Suzette Delaloge. (2021). BRCA2: a 25-year journey from gene identification to targeted cancer treatment. The Lancet Oncology. 22(6). 763–764. 1 indexed citations
20.
Grinda, Thomas, et al.. (2021). Mécanismes de résistance et d’échappement aux cellules CAR-T. Bulletin du Cancer. 108(10). S128–S140. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vichitra Behel Breakdown of academic impact, for papers by Samuel M. Niman Breakdown of academic impact, for papers by Qilong Zhang Breakdown of academic impact, for papers by Olga Ponomarova Breakdown of academic impact, for papers by Jagdish Shetty Breakdown of academic impact, for papers by Raquel von Schumann Breakdown of academic impact, for papers by Victoria Attaya Breakdown of academic impact, for papers by M. Untch Breakdown of academic impact, for papers by Zachary T. Olah Breakdown of academic impact, for papers by Samira Bensfia
Rankless by CCL
2026